News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vivaldi Biosciences Announces the Appointment of William Wainwright, PhD as Vice President, Vaccine Development


2/25/2009 10:27:17 AM

NEW YORK--(BUSINESS WIRE)--Vivaldi Biosciences Inc., a biotechnology company focused on the development of vaccines for influenza, today announced the appointment of William (Bill) H. Wainwright, PhD as Vice President, Vaccine Development. In this newly created position, Dr. Wainwright has responsibility for the development of Vivaldiā€™s live attenuated vaccine candidates for seasonal and pandemic influenza, from pre-clinical evaluation through Phase I/II clinical trials. His responsibilities include development of manufacturing processes and quality control procedures, and manufacture of clinical trial material in compliance with global quality standards.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES